ReviewCancers2019
Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Exhaled breath volatile organic compounds (VOCs) detection methods: GC-MS versus eNose in COPD diagnosis-a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Advanced strategy for cancer detection based on volatile organic compounds in breath.Journal of nanobiotechnology · 2025Pooled it
- A novel substrate for CYP3A4 phenotyping: in vitro biotransformation of hubamine into butanone.Analytical and bioanalytical chemistry · 2026Article
- The Role of Breath Analysis in the Non-Invasive Early Diagnosis of Malignant Pleural Mesothelioma (MPM) and the Management of At-Risk Individuals.Molecules (Basel, Switzerland) · 2025Observational
- A bibliometric analysis of malignant pleural mesothelioma from 2010 to 2023.Journal of thoracic disease · 2025Article
- Machine Learning Model Discriminate Ischemic Heart Disease Using Breathome Analysis.Biomedicines · 2024Article
- Clinical Perspectives and Novel Preclinical Models of Malignant Pleural Mesothelioma: A Critical Review.ACS pharmacology & translational science · 2024Review
- Breath Analysis: Identification of Potential Volatile Biomarkers for Non-Invasive Diagnosis of Chronic Kidney Disease (CKD).Molecules (Basel, Switzerland) · 2024Observational
- Breathomics Detect the Cardiovascular Disease: Delusion or Dilution of the Metabolomic Signature.Current cardiology reviews · 2024Review
- Volatilome is Inflammasome- and Lipidome-dependent in Ischemic Heart Disease.Current cardiology reviews · 2024Review
- Current Limitations of Staph Infection Diagnostics, and the Role for VOCs in Achieving Culture-Independent Detection.Pathogens (Basel, Switzerland) · 2023Review
- External Validation of a Breath-Based Prediction Model for Malignant Pleural Mesothelioma.Cancers · 2022Article
- Headspace Volatile Organic Compound Profiling of Pleural Mesothelioma and Lung Cancer Cell Lines as Translational Bridge for Breath Research.Frontiers in oncology · 2022Article
- A systematic review of the diagnostic accuracy of volatile organic compounds in airway diseases and their relation to markers of type-2 inflammation.ERJ open research · 2021Article
- Review
- New Biomarkers in Cancers.Cancers · 2021Article
- Breath Analysis: Comparison among Methodological Approaches for Breath Sampling.Molecules (Basel, Switzerland) · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant pleural mesothelioma (MPM) is a rare neoplasm related to asbestos exposure and with high mortality rate. The management of patients with MPM is complex and controversial, particularly with regard to early diagnosis. In the last few years, breath analysis has been greatly implemented with this aim. In this review the strengths of breath analysis and preliminary results in searching breath biomarkers of MPM are highlighted and discussed, respectively. Through a systematic electronic literature search, collecting papers published from 2000 until December 2018, fifteen relevant scientific papers were selected. All papers considered were prospective, comparative, observational case-control studies although every single one pilot and based on a relatively small number of samples. The identification of diagnostic VOCs pattern, through breath sample characterization and the statistical data treatment, allows to obtain a strategic information for clinical diagnostics. To date the collected data provide just preliminary information and, despite the promising results and diagnostic accuracy, conclusions cannot be generalized due to the limited number of individuals included in each cohort study. Furthermore none of studies was externally validated, although validation process is a necessary step towards clinical implementation. Breathomics-based biomarker approach should be further explored to confirm and validate preliminary findings and to evaluate its potential role in monitoring the therapeutic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.